Inflammatory Onset and Resolution MedDRA version: 20.1 Level: LLT Classification code 10053414 Term: Application site blister System Organ Class: 100000004867
Conditions
Interventions
Product Code: PL8177
Pharmaceutical Form: Solution for injection in pre-filled syringe
INN or Proposed INN: Not available
CAS Number: 1309111-58-7
Other descriptive name: PL8177
Concentration unit: mg
Sponsors
Palatin Technologies, Inc.
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Healthy male participants on the Fitzpatrick scale of 1 to 3, between 18 and 45 years of age, inclusive, at screening. 2. Body mass index between 18.0 and 30.0 kg/m2, inclusive, with body weight not less than 50 kg, at screening. 3. In good health, determined by no clinically significant findings from medical/surgical history, physical examination, vital sign measurements, 12-lead ECG, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia (e.g. Gilbert’s syndrome) is not acceptable at screening), as assessed by the Investigator (or designee). 4. A 12-lead ECG consistent with normal cardiac conduction and function at screening, including; HR between 45 and 100 bpm, QTcF interval less than or equal to 450 ms , QRS interval =65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Significant history or clinical manifestation of any medical illness including (but not limited to); metabolic, dermatological, hepatic, renal, haematological, pulmonary, cardiovascular, coagulation disorder, lipid abnormality, gastrointestinal (GI), immunologic, neurological, respiratory, endocrine, psychiatric disorder, or infectious disease (including tuberculosis), any other current physical condition that the Investigator considers should exclude the participant, or that could interfere with the interpretation of the study results as determined by the Investigator (or designee). 2. Participants with significant history of or clinical manifestation of a dermatologic disorder, including but not limited to psoriasis, severe acne, seborrhoea, and eczema. Mild to moderate acne limited to the face, chest, and shoulders is acceptable. The skin of the forearms must not be affected. 3. Has any clinically significant physical examination finding, ECG abnormality, or clinically significant abnormal value for clinical chemistry, haematology, coagulation, or urinalysis at screening or any significant physical exam finding, clinically significant abnormal value for clinical chemistry, haematology or urinalysis at baseline, as determined by the Investigator. 4. Has any of the following: a. Systolic blood pressure 140 mmHg at screening (measured in seated position) b. Diastolic blood pressure of 90 mmHg at screening (measured in seated position) c. Heart rate 100 bpm 5. Currently suffers from clinically significant systemic allergic disease as determined by the Investigator, or has a history of significant drug allergies, 6. Current systemic infection. 7. History or current manifestation of herpes infection of the eye. 8. History or current manifestation of galactose or lactose intolerance or glucosegalactose malabsorption. 9. History or current manifestation of severe depression or manic-depression (bipolar disorder), or if any close family member (parent, sibling, or offspring) has had severe depression or manic-depression, steroid psychosis, emotional instability, or psychotic tendencies. 10. Receipt of any live vaccine within 30 days prior to screening or intent to receive any live vaccine within 90 days following completion of the study. 11. History of adverse reaction to corticosteroid, including fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioural and mood changes, increased appetite and weight gain. 12. History or presence of malignancy within the past 5 years with the exception of adequately treated localised skin cancer (basal cell or squamous cell carcinoma) which is allowed. 13. Personal history or family history of melanoma (for the purposes of this study family history is defined as history in first-degree relatives i.e. parents or siblings). 14. History of hyperplastic, dysplastic or atypical nevi. 15. Has had an acute or clinically significant illness as determined by the Investigator, within 30 days prior to Day 1, or has had a recent febrile illness with an abnormal body temperature within 72 hours before dosing on Day 1. 16. History of alcoholism or drug/chemical abuse within 2 years prior to screening. 17. Has a positive test for hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus (HIV) at screening or has been previously treated for hepatitis B, hepatitis C or HIV infection. 18. Participation in a clinical study invol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To determine whether subcutaneous PL8177 compared to placebo alters blister fluid volume and blister fluid differential leukocyte numbers.;Secondary Objective: • Determine whether PL8177 alters blister fluid cytokine analysis • Determine whether PL8177 alters markers of inflammation resolution • Determine whether PL8177 alters peripheral markers of inflammation;Primary end point(s): • Difference in volume of blister fluid, as compared to placebo. • Difference in WBC count and differential in blister fluid, as compared to placebo.;Timepoint(s) of evaluation of this end point: Blister fluid collection will occur on Day 4. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): • Proportion of participants with reduced blister volume, blister fluid WBC count, and altered fluid differential, as compared to placebo. • Proportion of subjects with reduced inflammatory response to blister induction, compared with placebo, as indicated by: o Reduced blister fluid markers of cell activation o Altered blister fluid lipid mediator profile o Reduced blister and plasma cytokines/chemokines • Change of the following parameters, as compared to placebo: o Levels of blister fluid markers of cell activation o Change of blister fluid lipid mediator profile o Change of levels of blister and plasma cytokines/chemokines;Timepoint(s) of evaluation of this end point: Blister fluid collection will occur on Day 4. Inflammatory Markers, peripheral blood samples (cytokines/chemokines) will be collected on Day 1, 4, 11. | — |
Countries
United Kingdom
Contacts
Public ContactInformation
Palatin Technologies, Inc.
Outcome results
None listed